EuPFI 2021: Development of a Novel Pediatric Belumosudil Oral Suspension
Overview
Download Quotient Sciences' scientific poster entitled, 'EuPFI 2021 - Development of a Novel Paediatric Belumosudil Oral Suspension'.
Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders. A formulation was required suitable for a pediatric patient population aged between three months and twelve years. This development program aimed to develop a suitable, novel belumosudil oral suspension formulation using age-appropriate excipients to be used in a relative bioavailability assessment of the suspension compared to the reference adult tablet formulation. A liquid formulation enables flexible dosing by varying the dose volume according to the age and/or body weight of the patient.